Natural Products and Drug Discovery : (Record no. 136365)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11137nam a22005053i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5301616 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729131759.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2018 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780081021040 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780081020814 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5301616 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5301616 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11512867 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1023628137 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS164 .N388 2018 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Mandal, Subhash C. |
| 245 10 - TITLE STATEMENT | |
| Title | Natural Products and Drug Discovery : |
| Remainder of title | An Integrated Approach. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | San Diego : |
| Name of producer, publisher, distributor, manufacturer | Elsevier, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (778 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Front Cover -- Natural Products and Drug Discovery -- Natural Products and Drug Discovery -- Copyright -- Contents -- List of Contributors -- Foreword -- Preface -- I - Traditional Medicine and Drug Discovery -- 1 - Drug Discovery From Ayurveda: Mode of Approach and Applications -- 1. AYUSH AND AYURVEDA -- 2. CHRONOLOGICAL GENESIS OF AYURVEDIC DRUGS FOR THERAPEUTIC APPLICATION -- 3. FUNDAMENTAL PRINCIPLES OF PERSONALIZED MEDICINE, GENETIC STUDY, AND APPLIED ASPECTS OF AYURVEDIC PHARMACODYNAMICS -- 4. CLASSIFICATION OF AYURVEDIC THERAPEUTICS -- 4.1 Ayurvedic Treatment for the Promotion of Health -- 4.2 Treatment for the Prevention of Disease -- 4.3 Curative Management in Ayurveda -- 4.3.1 Curative Management With Plant Drugs -- 4.3.2 Metals and Minerals for Curative Management -- 4.3.3 Animal Products for Curative Management -- 5. SCIENTIFIC RESEARCH OF AYURVEDA FOR DRUG DEVELOPMENT FROM PLANT SOURCES -- 5.1 Rasayana Therapy -- 5.2 Diabetes Mellitus -- 5.3 Wound-Healing Drugs -- 5.4 Learning, Memory, and Cognitive Disorders -- 6. SCIENTIFIC RESEARCH OF AYURVEDA FOR DRUG DEVELOPMENT FROM METALS AND MINERALS -- 6.1 Drugs From Zinc: Jasada Bhasma -- 6.2 Iron Therapy in Ayurveda -- 6.3 Gold Therapy in Ayurveda -- 6.4 Shilajit: A Unique Molecule of Ayurveda -- 7. RECOMMENDATION -- REFERENCES -- 2 - Traditional and Folk Medicine as a Target for Drug Discovery -- 1. INTRODUCTION -- 2. DIFFERENT TRADITIONAL AND FOLK MEDICINES -- 2.1 Ayurveda -- 2.2 Maibaron -- 2.3 Traditional Chinese Medicine -- 2.4 Traditional Korean Medicine -- 2.5 African Medicine (Muti in South and Ifa in West) -- 2.6 Iranian Medicine -- 3. TAXOL AS A LEAD TO CANCER DRUG DISCOVERY -- 4. DEMAND FOR DRUGS FOR LIVER DISORDERS (HEPATIC DISEASE) -- 5. DEMAND FOR DRUGS FOR DENGUE -- 5.1 Targeting -and Controlling the Virus -- 5.1.1 Plant Sources -- 5.1.2 Compound Sources. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.1.3 Mushroom Sources -- 5.1.4 Formulations -- 5.2 Targeting -and Controlling the Vector Mosquito -- 6. CONCLUSION -- REFERENCES -- 3 - Bioactivity-Guided Phytofractions: An Emerging Natural Drug Discovery Tool for Safe and Effective Disease Manag ... -- 1. INTRODUCTION -- 2. WHY DO BIOACTIVITY-GUIDED PHYTOFRACTIONS EXHIBIT PROMISING ALLEVIATION AGAINST DISEASE MODELS -- 3. SEPARATION, CHARACTERIZATION, AND STANDARDIZATION OF TARGET DISEASE-SPECIFIC BIOACTIVITY-GUIDED FRACTIONS -- 4. SIGNIFICANCE AND UTILITY OF TARGET-ORIENTED, DISEASE-SPECIFIC, BIOACTIVITY-GUIDED PHYTOFRACTIONS -- 5. EXPERIMENTAL EVIDENCE IN FAVOR OF BIOASSAY-GUIDED PHYTOFRACTION AS A THERAPEUTIC TOOL -- 6. DISCUSSION AND CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- 4 - Development of Chinese Herbal Health Products for the Prevention of Aging-Associated Diseases -- 1. MITOCHONDRIAL DYSFUNCTION IN AGING-ASSOCIATED DISEASES -- 1.1 Cardiovascular Diseases -- 1.2 Neurodegenerative Diseases -- 1.3 Osteoporosis -- 1.4 Dysregulation of Immune Function -- 2. CONCEPTUAL BASIS OF PREVENTIVE HEALTH IN CHINESE MEDICINE -- 2.1 Yin-Yang Theory -- 2.2 Qi and Body Function -- 2.3 Restoring the Dynamic Balance Between Yin and Yang and Hence the Generation of Normal Qi Using Chinese Tonifying Herbs -- 3. PHARMACOLOGICAL BASIS OF THE HEALTH-PROMOTING ACTIONS OF CHINESE TONIFYING HERBS -- 3.1 Yang/Qi-Invigorating Action: Effects on Cellular Energy Metabolism and Mitochondrial Function -- 3.1.1 β-Sitosterol (Yang-Invigorating) -- 3.1.2 Ginsenosides (Qi-Invigorating) -- 3.1.3 Schisandrin B (Qi-Invigorating) -- 3.2 Yin-Nourishing/Blood-Enriching Action: Effects on Immune and Blood/Circulatory Functions -- 3.2.1 Oleanolic Acid (Yin-Nourishing) -- 3.2.2 Catalpol (Blood-Enriching) -- 4. CHINESE HERBAL TONIFYING FORMULAS -- 4.1 Wu-Zi-Yan-Zong-Wan (Yang-Invigorating) -- 4.2 Er-Zhi-Wan (Yin-Nourishing). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.3 Shengmai San (Qi-Invigorating) -- 4.4 Si-Wu-Tang (Blood-Enriching) -- 5. CONCLUSIONS -- REFERENCES -- 5 - Ethnobotany/Ethnopharmacology, and Bioprospecting: Issues on Knowledge and Uses of Medicinal Plants by Moroccan ... -- 1. INTRODUCTION -- 2. BRIEF HISTORY OF MEDICAL SCIENCES IN MUSLIM-ARAB CIVILIZATION -- 2.1 Sciences at a Glance in the Golden Age -- 2.1.1 Brief History of Medical Sciences -- 2.1.2 Evolution of Herbal Medical Sciences -- 3. TRADITIONAL MEDICINE IN MOROCCO -- 3.1 Current Medical Ethnobiological Studies in Morocco -- 3.2 Knowledge of Ethnobotany, Ethnomedicine, and Medicinal Plant Uses -- 3.3 The Trading of Medicinal Plants -- 4. CONSTRAINTS AND CHALLENGES FACING THE MEDICINAL PLANTS SECTOR -- 5. CONCLUSION -- REFERENCES -- 6 - Chemotaxonomy of Medicinal Plants: Possibilities and Limitations -- 1. INTRODUCTION -- 2. SECONDARY METABOLITES AS GUIDE FOR CLASSIFICATIONS -- 2.1 Alkaloid in Chemotaxonomy -- 2.2 Plant Phenol in Chemotaxonomy -- 2.3 Quinones in Chemotaxonomy -- 2.4 Glycosides in Chemotaxonomy -- 3. LIMITATIONS OF CHEMOTAXONOMIC CLASSIFICATION -- 4. SUMMARY AND FUTURE PROSPECTS -- REFERENCES -- II - Leads From Natural Products -- 7 - The Role of Natural Products From Plants in the Development of Anticancer Agents -- 1. INTRODUCTION -- 2. NATURAL PRODUCTS AND THEIR ANTICANCER ACTIVITY -- 2.1 Terpenoids -- 2.1.1 Mechanism of Action of Terpenoids -- 2.2 Flavonoids -- 2.2.1 Mechanism of Action of Flavonoids -- 2.3 Alkaloids -- 2.3.1 Mechanism of Action of Alkaloids -- 3. PLANT-DERIVED ANTICANCER DRUGS CURRENTLY IN USE AND IN CLINICAL TRIALS -- 3.1 Vincristine and Vinblastine -- 3.2 Etoposide and Teniposide -- 3.3 Paclitaxel and Docetaxel -- 3.4 Topotecan and Irinotecan -- 3.5 Elliptinium -- 3.6 Homoharringtonine -- 4. CELL LINE ABBREVIATIONS -- 5. CONCLUSION -- REFERENCES -- 8 - Plant Drugs in the Treatment of Osteoporosis. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1. INTRODUCTION -- 2. GLOBAL BURDEN OF OSTEOPOROSIS -- 3. MARKERS OF BONE METABOLISM -- 3.1 Markers of Bone Formation -- 3.2 Markers of Bone Resorption -- 4. SCREENING ASSAYS FOR OSTEOPOROSIS -- 4.1 Osteoblast Cultures -- 4.2 Osteoclast Cultures -- 4.3 The Ovariectomy Rat Model -- 5. OSTEOPROTECTIVE PLANT FORMULATIONS -- 6. ACTIVE CONSTITUENTS FROM PLANTS -- 6.1 Flavonoids -- 6.2 Isoflavonoids -- 6.3 Lignans -- 6.4 Coumarins -- 6.5 Alkaloids -- 6.6 Conclusions -- REFERENCES -- 9 - Phytodrugs and Immunomodulators for the Therapy of Leishmaniasis -- 1. LEISHMANIASIS -- 1.1 Overview of the Disease -- 1.2 Epidemiology -- 1.3 Life Cycle -- 1.4 Disease Manifestation -- 1.4.1 Geographical Classification -- 1.4.2 Clinical Classification -- 1.4.2.1 Visceral Leishmaniasis -- 1.4.2.2 Post-Kala-Azar Dermal leishmaniasis -- 1.4.2.3 Cutaneous Leishmaniasis -- 1.4.2.4 Mucosal and Mucocutaneous Leishmaniasis -- 1.4.2.5 HIV and Leishmaniasis Coinfection -- 1.5 Immunological Alterations in Host -- 2. THERAPEUTIC AGENTS FOR LEISHMANIASIS -- 2.1 Current Antileishmanial Drugs -- 2.1.1 Pentavalent Antimonials -- 2.1.2 Amphotericin B -- 2.1.3 Pentamidine Isethionate -- 2.1.4 Miltefosine -- 2.1.5 Paromomycin -- 2.1.6 Other Medications -- 2.2 Drug Resistance -- 2.3 Drug Toxicity and Side Effects -- 2.3.1 Pentavalent Antimonials -- 2.3.2 AmpB Deoxycholate -- 2.3.3 Liposomal Formulation of AmpB -- 2.3.4 Pentamidine Isethionate -- 2.3.5 Miltefosine -- 2.3.6 Paromomycin -- 2.4 Polychemotherapy for Leishmaniasis -- 2.5 Herbal Remedies -- 3. DRUG TARGETS IN LEISHMANIA -- 3.1 Polyamine Pathway -- 3.2 Thiol Metabolism -- 3.3 Sterol Pathway -- 3.4 Glucose Metabolism -- 3.5 Proteasome Pathway -- 4. APPROACHES FOR DRUG SCREENING OF NATURAL PRODUCT LIBRARIES AGAINST LEISHMANIA -- 4.1 Fluorescence Activated Cell Sorter-Based Assays -- 4.2 Plate Reader-Based Assays. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.3 Microscopy-Based High Content Assay -- 4.4 Animal Models Suitable for Drug Discovery and Development -- 5. PHYTOCHEMICALS WITH ANTILEISHMANIAL AND IMMUNOMODULATORY ACTIVITIES -- 5.1 Natural Products Drug Discovery -- 5.2 In Vivo Antileishmanial Phytochemicals -- 5.3 Antileishmanial Crude Plant Extracts -- 5.4 Plant Natural Product In Vitro Antileishmanial Agents and Immunomodulators -- 5.4.1 Alkaloids -- 5.4.2 Alkanes -- 5.4.3 Flavonoids -- 5.4.4 Phenylpropanoids -- 5.4.5 Quinones -- 5.4.6 Terpenoids -- 5.5 Marine and Fungal Natural Products With In Vitro Antileishmanial Activity -- 5.6 Combination Therapy -- 6. FUTURE DIRECTIONS AND CONCLUSIONS -- REFERENCES -- 10 - Natural Products Targeting Inflammation Processes and Multiple Mediators -- 1. INFLAMMATION RESPONSES AND PATHWAYS -- 1.1 Cellular Changes of Inflammatory Responses -- 1.2 Signaling Mediators of Inflammatory Responses -- 2. COMMON MEDIATORS OF INFLAMMATION PATHWAYS -- 2.1 Eicosanoids -- 2.1.1 PLA2 and the Production of AA and PAF -- 2.1.2 COXs and the Production of Prostaglandins, Thromboxanes, and Prostacyclin -- 2.1.3 5-LOs and the Production of LTs -- 2.2 Protein Kinase-Mediated IκB Degradation in the NF-κB Pathway -- 2.3 Inducible NO -- 2.4 Proinflammatory and Antiinflammatory Cytokines -- 2.5 Antiinflammatory Drugs Targeting Common Mediators -- 2.5.1 Glucocorticoids -- 2.5.2 NSAIDs -- 2.5.3 Biologics -- 3. NATURAL PRODUCTS TARGETING THE COMMON INFLAMMATORY MEDIATORS -- 3.1 Introduction and the Salicylate Story -- 3.2 Phenolics -- 3.3 Terpenes -- 3.4 Alkaloids -- 3.5 Others -- 4. ANTIINFLAMMATORY NATURAL PRODUCTS WITH MULTIPLE TARGETS -- 4.1 Introduction -- 4.2 Curcumin -- 4.3 (−)-Epigallocatechin-3-gallate -- 4.4 trans-Resveratrol -- 4.5 Quercetin -- 4.6 Racemosic Acid -- 5. CONCLUSION -- REFERENCES -- 11 - Biologically Functional Compounds From Mushroom-Forming Fungi. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1. ANTIDEMENTIA COMPOUNDS. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Materia medica, Vegetable. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Herbs--Therapeutic use. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mandal, Vivekananda. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Konishi, Tetsuya. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Mandal, Subhash C. |
| Title | Natural Products and Drug Discovery |
| Place, publisher, and date of publication | San Diego : Elsevier,c2018 |
| International Standard Book Number | 9780081020814 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5301616">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5301616</a> |
| Public note | Click to View |
No items available.